Equivalence studies for complex active ingredients and dosage forms
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 4
Abstract
This article examines the United States Pharmacopeia (USP) and its role in assessing the equivalence and inequivalence of biological and biotechnological drug substances and products—a role USP has played since its founding in 1820. A public monograph in theUnited States Pharmacopeia-National Formulary helps practitioners and other interested parties understand how an article’s strenght, quality, and purity should be controlled. Such a monograph is a standard to which all manufactured ingredients and products should conform, and it is a starting point for subsequent-entry manufactures, recognizing that substantial additional one-time characterization studies may be needed to document equivalence. Review of these studies is the province of the regulatory agency, but compendial tests can provide clarity and guidance in the process.
Authors and Affiliations
Lokesh Bhattycharyya, Roger Dabbah, Walter Hauck, Eric Sheinin, Lynn Yeoman, Roger Williams
Keywords
Related Articles
- EP ID EP681897
- DOI 10.1208/aapsj070477
- Views 85
- Downloads 0
Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers
The purpose of this study was to evaluate the effect of carrier particle size and simulated inspiratory flow increase rate on emptying from dry powder inhalers (DPIs). Several flow rate ramps were created using a compute...
Deorphanization of Novel Peptides and Their Receptors
Peptide hormones and neuropeptides play important roles in endocrine and neural signaling, often using G protein-coupled receptor (GPCR)-mediated signaling pathways. However, the rate of novel peptide discovery has slowe...
Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation
The endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA) produces most of its pharmacological effects by binding and activating CB1 and CB2 cannabinoid receptors within the CNS and periphery. However, the...
Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts
To date, there has been little investigation of the risk for drug–drug interactions involving monoclonal antibodies. The present work examined the effects of an anti-vascular endothelial growth factor (anti-VEGF)...
Systematic Verification of Bioanalytical Similarity Between a Biosimilar and a Reference Biotherapeutic: Committee Recommendations for the Development and Validation of a Single Ligand-Binding Assay to Support Pharmacokinetic Assessments
The online version of this article (doi:10.1208/s12248-014-9669-5) contains supplementary material, which is available to authorized users.